|
US6291425B1
(en)
*
|
1999-09-01 |
2001-09-18 |
Guilford Pharmaceuticals Inc. |
Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
|
|
US7329670B1
(en)
|
1997-12-22 |
2008-02-12 |
Bayer Pharmaceuticals Corporation |
Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
|
|
US7517880B2
(en)
|
1997-12-22 |
2009-04-14 |
Bayer Pharmaceuticals Corporation |
Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
|
|
US7351834B1
(en)
|
1999-01-13 |
2008-04-01 |
Bayer Pharmaceuticals Corporation |
ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
EP1690853B1
(en)
*
|
1999-01-13 |
2010-03-10 |
Bayer HealthCare LLC |
Use of omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
EP1140840B1
(en)
|
1999-01-13 |
2006-03-22 |
Bayer Pharmaceuticals Corp. |
-g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
US7928239B2
(en)
*
|
1999-01-13 |
2011-04-19 |
Bayer Healthcare Llc |
Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
|
|
HU230863B1
(hu)
*
|
1999-01-13 |
2018-10-29 |
Bayer Healthcare Llc |
Omega-karboxi-arilcsoporttal helyettesített difenil-karbamidok, mint raf-kináz inhibitorok
|
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
EP2298311B1
(en)
*
|
1999-01-13 |
2012-05-09 |
Bayer HealthCare LLC |
w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
|
|
CA2395564A1
(en)
|
1999-11-22 |
2001-05-31 |
Smithkline Beecham Plc |
Novel compounds
|
|
EP1263753B1
(en)
|
2000-03-06 |
2004-05-06 |
SmithKline Beecham plc |
Imidazol derivatives as raf kinase inhibitors
|
|
GB0005357D0
(en)
*
|
2000-03-06 |
2000-04-26 |
Smithkline Beecham Plc |
Compounds
|
|
US6645990B2
(en)
|
2000-08-15 |
2003-11-11 |
Amgen Inc. |
Thiazolyl urea compounds and methods of uses
|
|
KR100600550B1
(ko)
|
2000-10-20 |
2006-07-13 |
에자이 가부시키가이샤 |
질소 함유 방향환 유도체
|
|
US7238813B2
(en)
|
2000-11-29 |
2007-07-03 |
Smithkline Beecham Corporation |
Chemical compounds
|
|
US7235576B1
(en)
|
2001-01-12 |
2007-06-26 |
Bayer Pharmaceuticals Corporation |
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
UA76977C2
(en)
|
2001-03-02 |
2006-10-16 |
Icos Corp |
Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
|
|
JP2004528311A
(ja)
*
|
2001-03-07 |
2004-09-16 |
テリック，インコーポレイテッド |
Ｆａｓ媒介アポトーシスの刺激剤としての置換ジアリールウレア
|
|
ES2283543T3
(es)
*
|
2001-04-20 |
2007-11-01 |
Bayer Pharmaceuticals Corporation |
Inhibicion de raf kinasa usando quinolil-, isoquinolil- o piridil ureas.
|
|
US7371763B2
(en)
|
2001-04-20 |
2008-05-13 |
Bayer Pharmaceuticals Corporation |
Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
|
|
GB0112348D0
(en)
|
2001-05-19 |
2001-07-11 |
Smithkline Beecham Plc |
Compounds
|
|
AU2002317377A1
(en)
*
|
2001-07-20 |
2003-03-03 |
Cancer Research Technology Limited |
Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
|
|
US10653684B2
(en)
|
2002-02-11 |
2020-05-19 |
Bayer Healthcare Llc |
Aryl ureas with angiogenisis inhibiting activity
|
|
DK1478358T3
(da)
|
2002-02-11 |
2013-10-07 |
Bayer Healthcare Llc |
Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
|
|
ATE529406T1
(de)
|
2002-02-11 |
2011-11-15 |
Bayer Healthcare Llc |
Aryl-harnstoffe als kinase inhibitoren
|
|
WO2003068229A1
(en)
*
|
2002-02-11 |
2003-08-21 |
Bayer Pharmaceuticals Corporation |
Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
|
|
PE20040522A1
(es)
|
2002-05-29 |
2004-09-28 |
Novartis Ag |
Derivados de diarilurea dependientes de la cinasa de proteina
|
|
CA2493253A1
(en)
*
|
2002-08-01 |
2004-02-12 |
Neurosearch A/S |
Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy
|
|
US20040034038A1
(en)
*
|
2002-08-13 |
2004-02-19 |
Goaquan Li |
Urea kinase inhibitors
|
|
US7056925B2
(en)
|
2002-08-13 |
2006-06-06 |
Abbott Laboratories |
Urea kinase inhibitors
|
|
US7399866B2
(en)
|
2003-01-14 |
2008-07-15 |
Cytokinetics, Inc. |
Compounds, compositions, and methods
|
|
EP1603879A2
(en)
*
|
2003-02-28 |
2005-12-14 |
Bayer Pharmaceuticals Corporation |
Substituted pyridine derivatives useful in the treatment of cancer and other disorders
|
|
CA2516931C
(en)
|
2003-02-28 |
2014-09-09 |
Bayer Pharmaceuticals Corporation |
Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders
|
|
CA2526285A1
(en)
|
2003-05-15 |
2004-12-23 |
Arqule, Inc. |
Inhibitors of p38 and methods of using the same
|
|
EP1636585B2
(en)
|
2003-05-20 |
2012-06-13 |
Bayer HealthCare LLC |
Diaryl ureas with kinase inhibiting activity
|
|
NZ544331A
(en)
|
2003-07-22 |
2010-03-26 |
Arena Pharm Inc |
Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
|
|
PL1663978T3
(pl)
|
2003-07-23 |
2008-04-30 |
Bayer Healthcare Llc |
Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
|
|
DE10334663A1
(de)
*
|
2003-07-30 |
2005-03-10 |
Merck Patent Gmbh |
Harnstoffderivate
|
|
JP4303726B2
(ja)
|
2003-11-11 |
2009-07-29 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ウレア誘導体およびその製造方法
|
|
RU2006131045A
(ru)
*
|
2004-01-30 |
2008-03-10 |
Мерк Патент ГмбХ (DE) |
Производные бисарилмочевины
|
|
TW200530236A
(en)
|
2004-02-23 |
2005-09-16 |
Chugai Pharmaceutical Co Ltd |
Heteroaryl phenylurea
|
|
CN1926114B
(zh)
|
2004-03-23 |
2011-08-24 |
艾尼纳制药公司 |
用于制备经取代n-芳基-n′-′3-(1h-吡唑-5-基)苯基脲及其中间体的方法
|
|
US7838524B2
(en)
|
2004-04-30 |
2010-11-23 |
Bayer Healthcare Llc |
Substituted pyrazolyl urea derivatives useful in the treatment of cancer
|
|
US7507735B2
(en)
|
2004-06-17 |
2009-03-24 |
Cytokinetics, Inc. |
Compounds, compositions and methods
|
|
US8354427B2
(en)
|
2004-06-24 |
2013-01-15 |
Vertex Pharmaceutical Incorporated |
Modulators of ATP-binding cassette transporters
|
|
CA2881078C
(en)
|
2004-06-24 |
2018-10-02 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters
|
|
AU2005270102A1
(en)
*
|
2004-07-02 |
2006-02-09 |
Icos Corporation |
Compounds useful for inhibiting Chk1
|
|
WO2006010082A1
(en)
|
2004-07-08 |
2006-01-26 |
Arqule, Inc. |
1,4-disubstituted naphtalenes as inhibitors of p38 map kinase
|
|
EP1778648A2
(en)
*
|
2004-08-19 |
2007-05-02 |
ICOS Corporation |
Compounds useful for inhibiting chk1
|
|
MY191349A
(en)
*
|
2004-08-27 |
2022-06-17 |
Bayer Pharmaceuticals Corp |
New pharmaceutical compositions for the treatment of hyper-proliferative disorders
|
|
US8969379B2
(en)
|
2004-09-17 |
2015-03-03 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
|
|
MX2007004248A
(es)
|
2004-10-13 |
2007-06-12 |
Merck Patent Gmbh |
Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.
|
|
CA2584368A1
(en)
|
2004-10-19 |
2006-04-27 |
Arqule, Inc. |
Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
|
|
PE20061130A1
(es)
|
2004-11-19 |
2007-01-05 |
Arena Pharm Inc |
Derivados de 3-fenil-pirazol como moduladores del receptor de serotonina 5-ht2a
|
|
EP2397478A1
(en)
*
|
2005-01-14 |
2011-12-21 |
CGI Pharmaceuticals, Inc. |
1,3-diaryl substituted ureas as modulators of kinase activity.
|
|
ES2465469T3
(es)
|
2005-01-14 |
2014-06-05 |
Gilead Connecticut, Inc. |
Diaril ureas 1,3-sustituidas como moduladores de la actividad quinasa
|
|
DE602006017188D1
(de)
|
2005-03-07 |
2010-11-11 |
Bayer Schering Pharma Ag |
Pharmazeutische zusammensetzung mit einem omega-carboxyaryl-substituierten diphenylharnstoff zur behandlung von krebs
|
|
US7777040B2
(en)
|
2005-05-03 |
2010-08-17 |
Cgi Pharmaceuticals, Inc. |
Certain substituted ureas, as modulators of kinase activity
|
|
JP4989476B2
(ja)
|
2005-08-02 |
2012-08-01 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
血管新生阻害物質の効果を検定する方法
|
|
US7538223B2
(en)
|
2005-08-04 |
2009-05-26 |
Cytokinetics, Inc. |
Compounds, compositions and methods
|
|
WO2007018137A1
(ja)
|
2005-08-05 |
2007-02-15 |
Chugai Seiyaku Kabushiki Kaisha |
マルチキナーゼ阻害剤
|
|
US7825120B2
(en)
|
2005-12-15 |
2010-11-02 |
Cytokinetics, Inc. |
Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
|
|
TW200808321A
(en)
|
2005-12-15 |
2008-02-16 |
Cytokinetics Inc |
Certain chemical entities, compositions and methods
|
|
WO2007078815A2
(en)
|
2005-12-16 |
2007-07-12 |
Cytokinetics, Inc. |
Certain chemical entities, compositions, and methods
|
|
WO2007078839A2
(en)
|
2005-12-19 |
2007-07-12 |
Cytokinetics, Inc. |
Compounds, compositions and methods
|
|
LT1993360T
(lt)
|
2005-12-28 |
2017-06-12 |
Vertex Pharmaceuticals Incorporated |
N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
|
|
US8148417B2
(en)
|
2006-05-18 |
2012-04-03 |
Arena Pharmaceuticals, Inc. |
Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
|
|
CN104706637A
(zh)
|
2006-05-18 |
2015-06-17 |
卫材R&D管理有限公司 |
针对甲状腺癌的抗肿瘤剂
|
|
EP2027119A2
(en)
|
2006-05-18 |
2009-02-25 |
Arena Pharmaceuticals, Inc. |
Ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
|
|
NZ571829A
(en)
|
2006-05-18 |
2011-10-28 |
Arena Pharm Inc |
Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor
|
|
US20080045589A1
(en)
|
2006-05-26 |
2008-02-21 |
Susan Kelley |
Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer
|
|
JP5368096B2
(ja)
|
2006-08-28 |
2013-12-18 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
未分化型胃癌に対する抗腫瘍剤
|
|
TWI415845B
(zh)
|
2006-10-03 |
2013-11-21 |
Arena Pharm Inc |
用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
|
|
WO2008044688A1
(en)
*
|
2006-10-11 |
2008-04-17 |
Daiichi Sankyo Company, Limited |
Urea derivative
|
|
WO2008079972A2
(en)
|
2006-12-20 |
2008-07-03 |
Bayer Healthcare Llc |
4-{4- [ ({3-tert-butyl-1- [3- (hydroxymethyl) phenyl] - 1h- pyrazol- 5 -yl } carbamoyl) -amin o] -3-chlorophenoxy} -n-methylpyridine-2-carboxamide as an inhibitor of the vegfr kinase for the treatment of cancer
|
|
WO2008093855A1
(ja)
|
2007-01-29 |
2008-08-07 |
Eisai R & D Management Co., Ltd. |
未分化型胃癌治療用組成物
|
|
US20080234332A1
(en)
*
|
2007-03-20 |
2008-09-25 |
Xiong Cai |
Raf kinase inhibitors containing a zinc binding moiety
|
|
ES2421237T7
(es)
|
2007-08-15 |
2013-09-30 |
Arena Pharmaceuticals, Inc. |
Derivados de imidazo[1,2-a]piridin como moduladores del receptor serotoninérgico 5ht2a en el tratamiento de trastornos relacionados con el mismo
|
|
WO2009035949A2
(en)
*
|
2007-09-13 |
2009-03-19 |
Arete Therapeutics, Inc. |
Soluble epoxide hydrolase inhibitors
|
|
CA2704000C
(en)
|
2007-11-09 |
2016-12-13 |
Eisai R&D Management Co., Ltd. |
Combination of anti-angiogenic substance and anti-tumor platinum complex
|
|
NZ586418A
(en)
*
|
2007-12-19 |
2012-09-28 |
Cancer Rec Tech Ltd |
Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
|
|
WO2009111278A2
(en)
|
2008-02-29 |
2009-09-11 |
Array Biopharma Inc. |
Raf inhibitor compounds and methods of use thereof
|
|
AR072657A1
(es)
|
2008-02-29 |
2010-09-15 |
Genentech Inc |
Compuestos inhibidores de raf y metodos para su uso
|
|
CN101372475B
(zh)
*
|
2008-03-19 |
2012-01-04 |
南京工业大学 |
芳杂环取代的二苯脲类衍生物及其用途
|
|
WO2009123714A2
(en)
|
2008-04-02 |
2009-10-08 |
Arena Pharmaceuticals, Inc. |
Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
|
|
US20100074949A1
(en)
|
2008-08-13 |
2010-03-25 |
William Rowe |
Pharmaceutical composition and administration thereof
|
|
US12458635B2
(en)
|
2008-08-13 |
2025-11-04 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administrations thereof
|
|
TR201805216T4
(en)
|
2008-10-28 |
2018-06-21 |
Arena Pharm Inc |
COMPOSITIONS OF A USEFUL 5-HT2A SEROTONINE RECEPTOR MODULATOR FOR THE TREATMENT OF RELATED DISORDERS
|
|
US9126946B2
(en)
|
2008-10-28 |
2015-09-08 |
Arena Pharmaceuticals, Inc. |
Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
|
|
SI3330255T1
(sl)
|
2009-03-20 |
2021-03-31 |
Vertex Pharmaceuticals Incorporated |
Postopek izdelave regulatorja transmembranske prevodnosti pri cistični fibrozi
|
|
CA2771403C
(en)
|
2009-08-19 |
2015-02-24 |
Eisai R&D Management Co. Ltd. |
Quinoline derivative-containing pharmaceutical composition
|
|
WO2011025798A1
(en)
*
|
2009-08-28 |
2011-03-03 |
Glaxosmithkline Llc |
Compounds and methods
|
|
US8980891B2
(en)
|
2009-12-18 |
2015-03-17 |
Arena Pharmaceuticals, Inc. |
Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
|
|
CN102958523B
(zh)
|
2010-06-25 |
2014-11-19 |
卫材R&D管理有限公司 |
使用具有激酶抑制作用的组合的抗肿瘤剂
|
|
JP2013531067A
(ja)
|
2010-07-19 |
2013-08-01 |
バイエル ヘルスケア リミティド ライアビリティ カンパニー |
疾病及び状態の処置及び予防のためのフルオロ置換オメガ−カルボキシアリールジフェニル尿素を用いた組み合わせ薬
|
|
US8802700B2
(en)
|
2010-12-10 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
|
CN102134207B
(zh)
*
|
2011-01-14 |
2013-04-17 |
厦门大学 |
一种脲化合物及其制备方法和用途
|
|
AU2012246490B2
(en)
|
2011-04-18 |
2016-08-04 |
Eisai R&D Management Co., Ltd. |
Therapeutic agent for tumor
|
|
JP6038128B2
(ja)
|
2011-06-03 |
2016-12-07 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
|
|
PL2739139T3
(pl)
*
|
2011-08-03 |
2020-06-15 |
National Taiwan University |
Agoniści białkowej fosfatazy tyrozynowej 1 zawierającej domeny homologii z src 2 i sposoby leczenia z ich zastosowaniem
|
|
EP2819670B1
(en)
|
2012-02-27 |
2026-05-20 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical Composition and Their Administration
|
|
JPWO2014098176A1
(ja)
|
2012-12-21 |
2017-01-12 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
キノリン誘導体のアモルファス及びその製造方法
|
|
CA2912219C
(en)
|
2013-05-14 |
2021-11-16 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
|
US9629851B2
(en)
|
2013-09-20 |
2017-04-25 |
Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis |
ROCK in combination with MAPK pathway
|
|
WO2015041534A1
(en)
|
2013-09-20 |
2015-03-26 |
Stichting Het Nederlands Kanker Instituut |
P90rsk in combination with raf/erk/mek
|
|
US20170027940A1
(en)
|
2014-04-10 |
2017-02-02 |
Stichting Het Nederlands Kanker Instituut |
Method for treating cancer
|
|
WO2015178770A1
(en)
|
2014-05-19 |
2015-11-26 |
Stichting Het Nederlands Kanker Instituut |
Compositions for cancer treatment
|
|
SG10201900631TA
(en)
|
2014-08-01 |
2019-02-27 |
Nuevolution As |
Compounds active towards bromodomains
|
|
EP3187491A4
(en)
|
2014-08-28 |
2018-08-01 |
Eisai R&D Management Co., Ltd. |
High-purity quinoline derivative and method for manufacturing same
|
|
CA2963945C
(en)
|
2014-10-07 |
2023-01-10 |
Vertex Pharmaceuticals Incorporated |
Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
|
|
US9638690B2
(en)
|
2014-11-07 |
2017-05-02 |
The University Of British Columbia |
Compounds and compositions for use as alkylating agent sensors and methods of use thereof
|
|
US20180028662A1
(en)
|
2015-02-25 |
2018-02-01 |
Eisai R&D Management Co., Ltd. |
Method for Suppressing Bitterness of Quinoline Derivative
|
|
KR20240064733A
(ko)
|
2015-03-04 |
2024-05-13 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
|
CN104817493A
(zh)
*
|
2015-03-11 |
2015-08-05 |
西安交通大学 |
一种芳杂环酰胺取代的二芳基脲化合物及其制备方法和应用
|
|
CN104744350A
(zh)
*
|
2015-03-11 |
2015-07-01 |
西安交通大学 |
一种吡啶取代的二芳基脲化合物及其制备方法和应用
|
|
JP2018516992A
(ja)
|
2015-06-12 |
2018-06-28 |
アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ |
レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
|
|
CA2988707C
(en)
|
2015-06-16 |
2023-10-10 |
Eisai R&D Management Co., Ltd. |
Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
|
|
CN108472285A
(zh)
|
2015-07-15 |
2018-08-31 |
阿速万科学有限责任公司 |
用于预防和治疗与神经退行性疾病相关联的幻觉的二芳基和芳基杂芳基脲衍生物
|
|
WO2017016523A1
(zh)
*
|
2015-07-30 |
2017-02-02 |
正大天晴药业集团股份有限公司 |
靶向idh2突变的抗肿瘤化合物及其使用方法
|
|
CN108135894B
(zh)
|
2015-08-20 |
2021-02-19 |
卫材R&D管理有限公司 |
肿瘤治疗剂
|
|
CN110072528B
(zh)
|
2017-02-08 |
2022-04-26 |
卫材R&D管理有限公司 |
治疗肿瘤的药物组合物
|
|
WO2018212202A1
(en)
|
2017-05-16 |
2018-11-22 |
Eisai R&D Management Co., Ltd. |
Treatment of hepatocellular carcinoma
|
|
CN108997209B
(zh)
*
|
2018-06-11 |
2020-08-04 |
山东罗欣药业集团恒欣药业有限公司 |
一种瑞戈非尼的制备方法
|
|
CN110128299B
(zh)
*
|
2019-05-13 |
2020-11-10 |
浙江大学 |
一种二苯基脲类抗肿瘤小分子抑制剂及其制备方法
|
|
CN113121484A
(zh)
|
2019-12-31 |
2021-07-16 |
复星弘创(苏州)医药科技有限公司 |
一种制备3-位被酰胺基烷基取代的香豆素类化合物的方法及其产物和相关中间体
|
|
WO2022203395A1
(ko)
*
|
2021-03-23 |
2022-09-29 |
한국과학기술연구원 |
신규한 화합물 및 이를 포함하는 퇴행성 뇌질환 예방 또는 치료용 조성물
|